2 enrolling by invitation, 2 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Akouos, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy Vestibular Schwannoma | Enrolling by invitation | Akouos, Inc. | 100 | 2026-03-02 | 2026-07-16 | |
| Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma | Phase 1 / Phase 2 | Recruiting | Akouos, Inc. | 27 | 2025-01-17 | 2026-04-06 |
| Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy Otoferlin Gene-mediated Hearing Loss | Enrolling by invitation | Akouos, Inc. | 30 | 2024-11-11 | 2026-04-06 | |
| Otoferlin Gene-mediated Hearing Loss Natural History Study Natural History Study - Sensorineural Hearing Loss, Bilateral | Recruiting | Akouos, Inc. | 150 | 2022-07-14 | 2026-03-04 |
Hearing Loss (3) · Auditory neuropathy (2) · Hearing Loss, Sensorineural (2) · Neuroma, Acoustic (2) · Deafness (1) · Deafness, Autosomal Recessive 9 (1) · Hearing Loss, Bilateral (1)
United States (4) · Spain (2) · Taiwan (2) · Australia (1) · Germany (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Aaron Tward, MD (2) · Peter Marks, M.D. (1) · Peter Marks, MD (1)